Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAssembly Biosciences Inc

Assembly Biosciences Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
21.13 USD 0.71 ( 3.48%)
Last update at 2026-11-09T15:41:00Z
VOLUME
88485
Market Cap
106.12M

Momentum Score

…

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
20.02
Low
21.23
High
52 Week Price Range
8.64
Low
19.93
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Assembly Biosciences is a clinical-stage biotech developing oral antivirals for chronic hepatitis B, focused on capsid assembly modulators and combination regimens intended to achieve a finite functional cure. Long-term growth may be driven by positive clinical data, regulatory approvals and commercial adoption across a large global HBV population, making the pipeline's late-stage readouts a key value driver.
Principal risks are binary clinical and regulatory outcomes, significant R&D cash burn with likely financing needs, and competition from other HBV modalities that could limit uptake.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
20.42
Dividend Yield
-
Revenue TTM
21.48M
Revenue Per Share
4.12
Gross Profit TTM
-63.90M
Debt / Equity
0.06
ROE
-101.78%
Net Debt
-17.50M
ROCE
-96.30%
Diluted EPS TTM
-6.89

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -93.09M -132.39M -62.15M -98.41M -89.65M
Net income -92.07M -129.85M -59.53M -97.63M -90.75M
Selling general administrative 24.13M 28.78M 37.06M 32.92M 34.80M
Gross profit - 6.25M 79.11M 15.96M 14.80M
Reconciled depreciation 0.50M 0.47M 0.69M 0.49M 0.64M
Ebit -94.61M -132.69M -64.78M -103.21M -92.73M
Ebitda -94.11M -49.41M -64.08M -102.71M -92.09M
Depreciation and amortization 0.50M 83.28M 0.69M 0.49M 0.64M
Non operating income net other 1.02M - 2.62M 4.30M 3.08M
Operating income -94.11M -132.69M -64.78M -102.71M -92.73M
Other operating expenses 94.11M 97.30M 143.88M 118.68M 107.54M
Interest expense -0.50M 82.51M 2.62M 4.80M 0.00M
Tax provision 0.00M -2.53M 0.00M -0.77M 1.10M
Interest income 1.02M 0.30M 2.62M 4.30M 3.08M
Net interest income 1.02M 0.30M 2.62M 4.30M 3.08M
Income tax expense -1.02M -2.53M -2.62M -0.77M 1.10M
Total revenue 0.00M 6.25M 79.11M 15.96M 14.80M
Total operating expenses 94.11M 97.30M 143.88M 118.68M 107.54M
Cost of revenue - - - 85.76M 107.54M
Total other income expense net 1.02M 0.30M 2.62M 4.30M 3.08M
Net income from continuing ops -93.09M -129.85M -62.15M -97.63M -90.75M
Net income applicable to common shares -93.09M -129.85M -62.15M -97.63M -90.75M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 137.47M 101.79M 191.06M 283.25M 339.91M
Intangible assets - - - 29.00M 29.00M
Other current assets 3.50M 4.41M 7.24M 6.85M 5.36M
Total liab 96.37M 19.13M 22.13M 42.68M 66.69M
Total stockholder equity 41.10M 82.66M 168.93M 240.58M 273.22M
Deferred long term liab - - 0.20M 2.53M 2.53M
Other current liab 6.63M 7.71M 7.53M 7.44M 13.11M
Common stock 0.01M 0.05M 0.05M 0.03M 0.03M
Capital stock 0.01M 0.05M 0.05M 0.03M 0.03M
Retained earnings -785.75M -724.52M -631.43M -501.57M -439.42M
Other liab - - 2.73M 11.52M 33.17M
Good will - - 0.00M 12.64M 12.64M
Other assets 0.00M - 1.70M 6.39M 1.68M
Cash 19.84M 52.42M 45.63M 59.44M 46.73M
Total current liabilities 39.23M 16.30M 16.07M 24.43M 24.44M
Current deferred revenue 30.91M 2.73M 2.73M 8.99M 6.41M
Net debt -17.50M -48.95M -39.15M -49.31M -34.46M
Short term debt 1.22M 3.36M 3.15M 3.40M 3.19M
Short long term debt total 2.34M 3.46M 6.48M 10.13M 12.27M
Other stockholder equity 826.92M 807.94M 800.73M 742.39M 712.81M
Property plant equipment - 0.74M 7.18M 1.60M 1.83M
Total current assets 133.79M 96.97M 154.20M 224.49M 282.78M
Long term investments - 0.00M 27.97M - -
Net tangible assets - 82.66M 168.93M 198.94M 231.58M
Short term investments 110.41M 39.19M 101.00M 156.97M 227.31M
Net receivables 0.04M 0.94M 0.34M 1.23M 3.37M
Inventory 0.00M - -101.00M - -
Accounts payable 0.46M 2.49M 2.66M 4.60M 1.73M
Accumulated other comprehensive income -0.08M -0.80M -0.42M -0.27M -0.20M
Common stock total equity - 0.05M - 0.03M 0.03M
Retained earnings total equity - -724.52M - -501.57M -439.42M
Non currrent assets other 0.31M 0.89M 1.70M 6.39M 1.68M
Non current assets total 3.68M 4.83M 36.86M 58.76M 57.13M
Capital lease obligations 2.34M 3.46M 6.48M 10.13M 12.27M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 89.24M 27.25M 70.29M -48.76M -135.06M
Change to liabilities 0.29M -8.19M 6.32M 1.32M -0.06M
Total cashflows from investing activities 90.64M 26.52M 68.07M -50.32M -135.40M
Total cash from financing activities 0.61M 53.06M 7.60M 139.65M 159.79M
Change to operating activities - -4.10M -7.26M -3.01M -0.49M
Net income -93.09M -129.85M -62.15M -97.63M -90.75M
Change in cash 6.79M -13.82M 12.71M 5.26M -40.56M
Begin period cash flow 45.63M 59.44M 46.73M 41.47M 82.03M
End period cash flow 52.42M 45.63M 59.44M 46.73M 41.47M
Total cash from operating activities -84.46M -93.40M -62.96M -84.07M -64.96M
Issuance of capital stock 0.33M 52.81M 5.45M 134.66M 155.43M
Depreciation 0.50M 0.47M 0.69M 0.49M 0.64M
Other cashflows from investing activities 1.50M - -1.75M -48.76M -135.06M
Change to inventory - -4.10M -7.26M -3.01M -0.60M
Change to account receivables -0.61M 0.89M 2.14M -0.94M -0.16M
Sale purchase of stock 0.61M - 7.60M 139.65M 159.79M
Other cashflows from financing activities 0.29M 0.26M 2.15M 4.99M 4.37M
Change to netincome 10.10M 47.39M 28.83M 24.34M 29.58M
Capital expenditures 0.10M 3.10M 2.22M 1.55M 0.34M
Change receivables -0.61M - 2.14M -0.94M -0.16M
Cash flows other operating -1.65M - -38.78M -11.64M -3.99M
Cash and cash equivalents changes 6.79M - 12.71M 5.26M -40.56M
Change in working capital -2.12M -11.40M -30.31M -9.53M -4.21M
Stock based compensation 6.59M 5.24M 21.85M 20.56M 28.48M
Other non cash items 3.66M 44.69M 6.96M 2.82M -0.23M
Free cash flow -84.56M -96.49M -65.18M -85.62M -65.30M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ASMB
Assembly Biosciences Inc		 0.71
3.48%		 21.13 - - 4.94 3.92 0.30 0.42
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Assembly Biosciences Inc

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Two Tower Place, South San Francisco, CA, United States, 94080

833 509 4583

https://www.assemblybio.com

65

Name Title Year Born
Dr. John G. McHutchison A.O., FRACP, M.D. CEO & Director 1957
Mr. Jason A. Okazaki COO & Pres 1976
Dr. William E. Delaney IV, Ph.D. Chief Scientific Officer 1972
Dr. Uri A. Lopatin M.D. Co-Founder and Clinical & Scientific Advisor 1972
Dr. Adam Zlotnick Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory Board NA
Ms. Jennifer A. Troia MHROD, SHRM-SCP, SPHR Chief HR Officer NA
Dr. Richard J. Colonno Sr. Advisor 1950
Dr. Tharaknath Rao Head of Microbiome Clinical Devel. & Sr. VP NA
Ms. Michele Anderson Chief Devel. Officer NA
Dr. Nicole S. White Ph.D. Chief Manufacturing Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.93
+37.83%
MOON
CAD 4.86
+10.20%
HG
CAD 4.43
+9.93%
EPRX
CAD 10.57
+8.86%
NUAG
CAD 8.66
+8.79%
CSU
CAD 3257.60
-7.63%
DIV
CAD 3.85
-5.53%
TOI
CAD 99.00
-5.52%
BSX
CAD 0.82
-4.65%
LMN
CAD 26.79
-4.63%

Equity Sectors*

  • Basic Materials

    +3.88%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.16%

  • Financial Services

    +1.33%

  • Healthcare

    +1.50%

  • Industrials

    +2.97%

  • Real Estate

    +0.41%

  • Technology

    +1.27%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…